Insulin,glucagon, and amino acids during glycemic control by the artificial pancreas in diabetic man

The artificial endocrine pancreas (AEP) can normalize glycemia at rest and with meals. To determine whether insulin, glucagon, and amino acid profiles are also normalized, nine diabetics on subcutaneous insulin ($\text{S}\text{C}$) and AEP control were compared to ten normal controls (NC). Glycemia was monitored continuously over 10 hr during which meals were consumed. Insulin infusion rate, and the levels of immunoreactive insulin (IRI) (in NC), free insulin (in $\text{S}\text{C}$ and AEP), C-peptide, glucagon, and amino acids are reported. Glycemia in AEP started at somewhat higher levels than in NC, but with breakfast and thereafter, it was identical. In $\text{S}\text{C}$, hyperglycemia prevailed throughout, with no systematic change in free IRI. In AEP, both basal and peak free insulin levels, measured in four patients, were significantly higher than in NC. C-peptide values were significantly lower in diabetics and did not change with meals. Basal glucagon values were not different in the three groups and changes with meals were of small magnitude. Branched chain amino acids were higher in $\text{S}\text{C}$ and did not increase as in NC. In AEP, levels were lower than NC after the first two meals. Similarly, lysine and threonine were lower in AEP than in NC at the same times. Alanine, though similar at the onset, was lower 2 hr postbreakfast and higher 2 hrs postsupper in AEP and $\text{S}\text{C}$ compared to NC. These studies demonstrate that glycemic control with AEP is accompanied by hyperinsulinemia, which could account for the amino acid responses and the small alterations in immunoreactive glucagon (IRG) patterns. Further refinement is needed to obtain full normalization of metabolic profiles.     

Effect of clofibrate on arginine-stimulated glucagon and insulin secretion in man

Insulin and glucagon have been reported to have opposing effects upon the mechanisms regulating serum triglyceride concentration. Glucagon in excess of insulin will lower serum lipids in man. In the present studies, we have examined the possibility that a change in glucagon and insulin regulation might contribute to the hypolipemic action of the drug clofibrate. Control insulin and glucagon secretion were evaluated in 24 normal subjects by intravenous arginine infusion, which resulted in a prompt rise in both serum immunoreactive insulin and glucagon concentration. During the maximum rise in concentration of these hormones, plasma triglyceride concentration was acutely reduced from basal levels of $\text{104 ± 6}\text{mg}\text{100}\text{ml}$ to $\text{75 ± 5}\text{mg}\text{100}\text{ml}$ (p ≤ 0.001). Following 7 days of clofibrate therapy, basal plasma triglyceride concentration attained a new mean level of $\text{78 ± 5}\text{mg}\text{100}\text{ml}$, while basal insulin and glucagon concentrations remained unchanged. However, arginine infusion now resulted in a reduction of the insulin secretory response to 56% of the preclofibrate studies with an associated normal glucagon secretory response. Serum triglyceride concentration was further reduced during arginine infusion to $\text{46 ± 3}\text{mg}\text{100}\text{ml}$, demonstrating this minimum level as maximum plasma glucagon levels were attained, representing an excess of this hormone relative to the reduced insulin concentration. These observations are consistent with an effect of clofibrate on the hormonal regulation of triglyceride physiology in man. Glucose tolerance was unimpaired by clofibrate therapy in these normal subjects, in spite of an apparent reduction in glucose-stimulated insulin secretion.     

Effect of glucagon on amino acid and nitrogen metabolism in fasting man

The infusion of small amounts of glucagon into fasting subjects has been reported to paradoxically decrease urinary urea nitrogen excretion. The mechanism and tissues by which this apparent protein sparing was accomplished was examined in the current study by infusing glucagon ($\text{0.1 mg}\text{24 hr × 4}\text{days}$) into subjects who had fasted for 5–6 wk. It was found that circulating levels of alanine and glutamine declined while urinary urea nitrogen excretion decreased and ammonia nitrogen excretion increased. These findings suggested that hepatic gluconeogenesis had been diminished while renal ammoniagenesis and gluconeogenesis had increased. The further finding of a significant prolongation of the $\text{t}\text{,}\text{1}\text{2}$ of ¹⁴C-lalanine (U) 24 hr after the start of the infusion appeared to substantiate this diminution in hepatic gluconeogenesis. In addition, while serum insulin levels had declined significantly by the end of the infusion, circulating levels of the branched-chain amino acids had increased. It was concluded that the infusion of small amounts of glucagon may have resulted in a diminution of portal glucagon levels, which in turn resulted in a decrease in hepatic gluconeogenesis and, directly or indirectly, a compensatory increase in renal ammoniagenesis and gluconeogenesis. The coincidental decline in alamine and the increase in levels of the branched-chain amino acids suggest that the infused glucagon had affected peripheral amino acid metabolism as well.     

Effect of changes in plasma levels of free fatty acids on plasma glucagon,insulin, and growth hormone in man

A regulatory role of acute changes in plasma concentration of free fatty acids on glucagon secretion has been suggested. We have studied the effect of such changes on plasma levels of glucagon, insulin, and growth hormone in man. Basal plasma levels of immunoreactive glucagon (IRG) were only slightly raised in 11 healthy subjects when the mean concentration of free fatty acids (FFA) was depressed to levels as low as 0.315 ± 0.043 (SEM) mM by infusion of nicotinic acid. Basal levels were increased modestly when the mean FFA level was elevated to 3.027 ± 0.184 mM by infusion of a triglyceride emulsion (Intralipid) with heparin. The plasma IRG response to intravenous arginine was unaffected by high or low levels of plasma FFA. These findings contrasted with the effects upon plasma levels of immunoreactive insulin (IRI) and growth hormone (IGH). During elevation of FFA levels, the mean basal level of plasma IRI increased by 100%, and the IRI response to arginine increased by 50%. Concomitantly, basal IGH levels and the plasma IGH response to arginine were suppressed markedly by elevation of FFA levels. The results of these studies do not offer support for a significant role of variation in plasma level of FFA as a regulator of acute changes in plasma IRG in man. An influence of changing levels of FFA on insulin secretion was found, and an effect on levels of growth hormone was confirmed.     

Effect of clofibrate on arginine-induced insulin and glucagon secretion

The influence of clofibrate therapy on insulin and glucagon secretion was examined in the rat. Following arginine stimulation, serum insulin and glucagon levels rose significantly, resulting an an $\text{I}\text{G}$ molar ratio of 1.0 ± 0.3. In contrast, clofibrate therapy completely suppressed the arginine-stimulated insulin secretion, but potentiated the simultaneous glucagon response. The resulting $\text{I}\text{G}$ molar ratio fell to 0.45 ± 0.06, consistent with a change in the bihormonal status in the direction of increased catabolism. These effects on hormonal balance may mediate in part the hypolipemic action of clofibrate that simultaneously occurs.     

Paradoxic elevation of serum growth hormone levels after splenectomy and/or paraesophagogastric devascularization in patients with portal hypertension

Blood glucose, serum immunoreactive insulin (IRI), and serum growth hormone (GH) levels during 50-g oral glucose tolerance tests (OGTT) were determined before and after splenectomy with or without paraesophagogastric devascularization in patients with portal hypertension (13 liver cirrhosis and 8 idiopathic portal hypertension) and in 5 splenectomized patients with diseases other than portal hypertension. Before splenectomy with devascularization, only 1 of 15 patients with portal hypertension exhibited a paradoxic elevation of serum GH levels of more than 10 ng/ml above the fasting levels after glucose loads. After the operation, however, 10 of these 15 patients showed the paradoxic elevation. Frequency of the paradoxic elevation was significantly higher after the operation than before (p < 0.001). The abnormal response of serum GH levels to glucose loads did not correlate with any of the blood glucose concentrations, serum IRI levels, and values for liver function tests. The paradoxic elevation was also observed in 4 of 6 patients with portal hypertension who underwent splenectomy alone without devascularization. These 4 patients with paradoxic elevation were splenectomized 4 wk and $\text{2}\text{1}\text{2}$, 20, and 29 yr previously. However, none of 5 splenectomized patients without portal hypertension showed the paradoxic elevation. The reason why the paradoxic elevation was observed after splenectomy only in patients with portal hypertension but not in patients without portal hypertension may be sought for in the changes of portal venous flow rather than splenectomy itself.     

Effect of dichloroacetate on gluconeogenesis in vivo in the presence of a fixed gluconeogenic substrate supply to the liver

Administration of dichloroacetate (DCA) to conscious 48 h fasted dogs causes a reduction in the conversion of circulating alanine and lactate to glucose coincident with both a reduction in the load of alanine and lactate delivered to the liver and a decrease in the plasma insulin-glucagon ($\text{I}\text{G}$) molar ratio. To determine whether DCA inhibits gluconeogenesis independent of its effect on alanine and lactate levels, the drug was infused concurrently with alanine and lactate in order to fix the load of these gluconeogenic precursors reaching the liver. When the circulating levels of alanine and lactate were fixed, DCA increased the net hepatic uptake of alanine markedly (98 ± 26%) but increased lactate uptake only slightly (8 ± 7%). However, the fraction of these gluconeogenic precursors which were converted to ¹⁴C-glucose decreased. Since the net effect of these changes was to increase the overall conversion of alanine and lactate to glucose, it is evident that the increase in precursor uptake overrode the inhibition of the gluconeogenic process per se. This increase in hepatic precursor uptake may have been due to DCA stimulation of pyruvate dehydrogenase activity or the observed decline in the $\text{I}\text{G}$ molar ratio. The observed increase in overall glucose production (33 ± 10%) was probably attributable to the increase in gluconeogenesis as well as an increase in glycogenolysis since 48 h fasted dogs still have some hepatic glycogen (15 mg/gm). By overcoming the peripheral effects of DCA on gluconeogenic precursor supply it becomes evident that DCA has: (1) a direct inhibitory action on intrahepatic gluconeogenesis, and (2) an effect on the pancreas which by virtue of a change in the $\text{I}\text{G}$ molar ratio may offset the direct intrahepatic effect of the drug.     

Effects of insulin on the response of immunoreactive glucagon to an intravenous glucose load in human diabetes.

The effects of exogenous insulin upon the response of immunoreactive glucagon (IRG) to i.v. glucose were studied in diabetic and nondiabetic subjects. In nondiabetics, a rapid injection of 25 g of glucose lowered plasma IRG levels. In adult-onset diabetics, the glucose-induced decline in IRG was normal despite a subnormal glucose-induced insulin rise, in contrast to impaired IRG suppressibility previously reported when such patients received an oral glucose load. The magnitude of their glucose-induced IRG decline was not augmented by exogenous insulin, even when insulin levels were acutely raised above 300 micro units/ml. In juvenile-type diabetics, basal IRG levels were normal following overnight insulin infusion, but the glucose-induced IRG decline was only half that of the nondiabetics. However, it became normal when hyperinsulinemia was acutely produced by supplementary insulin. Thus, whenever insulin levels rise in response to an increase in hyperglycemia, as they do spontaneously in nondiabetics and in adult-type diabetics and as they do when juvenile diabetics are given supplementary insulin together with the glucose bolus, the decline in IRG in response to an i.v. glucose load is as great as in nondiabetics. The findings are compatible with the view that glucose-induced suppression of IRG may require a concomitant rise in insulin.     

Oxytocin stimulates glucagon and insulin secretion in fetal and neonatal sheep

In adults of several species arginine vasopressin (AVP) and oxytocin (OT) stimulate pancreatic secretion of immunoreactive plasma glucagon (IRG). In fetal sheep AVP is an important stress hormone and may be simultaneously secreted with OT; however, their effects on IRG secretion are not known. We sought to determine if AVP and/or OT affected pancreatic IRG secretion in fetal and neonatal sheep. Either AVP or OT was infused for 30 min in chronically catheterized fetal and neonatal sheep, obtaining peripheral arterial and/or portal venous blood samples before; 10, 15, and 30 min during; and 15, 30, and 60 min after infusion for measurements of blood gases, hematocrit, IRG, immunoreactive plasma insulin (IRI) and plasma glucose. AVP did not affect IRG or IRI in fetal sheep (mean +/- SE, 133 +/- 1 days gestation), but small increases occurred in portal venous blood of lambs (2-49 days old). In contrast, OT (4.6 +/- 0.3 mU/min.kg; n = 12) increased fetal plasma IRG from 72 +/- 5 to 86 +/- 6 and 97 +/- 7 pg/ml (P less than 0.001) and IRI from 16 +/- 2 to 20 +/- 3 and 20 +/- 2 microU/ml (P less than 0.02) at 15 and 30 min, respectively; 157 +/- 11 microU OT/min.kg had no effect. In lambs (2-49 days old), 3.0 mU OT/min.kg increased arterial (n = 15) IRG from 139 +/- 19 to 367 +/- 43 and 483 +/- 76 pg/ml (P less than 0.01) and portal IRG (n = 8) from 167 +/- 39 to 341 +/- 72 and 502 +/- 148 pg/ml (P less than 0.01), respectively. Arterial and portal IRI also rose (P less than 0.01) from 36 +/- 4 to 82 +/- 12 and 105 +/- 32 microU/ml and from 29 +/- 5 to 65 +/- 13 and 51 +/- 7 microU/ml, respectively. Glucose was unchanged in all experiments. In fetal and neonatal sheep, AVP has minimal effects on IRG and IRI release. In contrast, OT increases both substantially; furthermore, there is a difference in fetal and neonatal responsiveness. OT may be important in modulating glucagon and insulin secretion during and after parturition.     

Lowering of fasting and food stimulated serum immunoreactive gastric inhibitory polypeptide (GIP) by glucagon.

The effect of intravenous glucagon infusion on serum levels of immunoreactive GIP (IR-GIP), insulin (IRI), gastrin (IRG), and on blood glucose has been investigated in six healthy volunteers in the fasting state and during ingestion of a mixed standard meal. Glucagon (500 ng/kg/min) lowered significantly serum levels of IR-GIP and IRG below the fasting values and increased the levels of IRI and blood glucose. Glucagon (50 ng/kg/min) infused 30 minutes before and continued 90 minutes after ingestion of a test meal abolished the IR-GIP response, suppressed significantly the IRG response, and left the IRI response unchanged. The same glucagon dose infused 60 minutes after ingestion of the test meal decreased significantly the raised levels of IR-GIP and IRG to fasting levels without changing IRI values. It is concluded that exogenous glucagon inhibits Gip release at the level of the GIP-producing cells.     

Impaired alpha cell function in conditions with cortisol deficiency

Plasma immunoreactive glucagon (IRG), insulin (IRI) and blood glucose (BG) were evaluated in the fasting state and during an arginine test (ATT) in 6 subjects with untreated hypopituitarism (H), in 2 hypopituitary subjects with normal cortisol production (H+C), in 3 subjects with Addison's disease (A) and in 14 normal volunteers (N). No increase in BG was observed in H and A after arginine, mean values being significantly lower than in N. Mean fasting and arginine-stimulated IRI levels were lower in H and A than in N; postabsorptive arginine-induced IRG levels were significantly reduced when compared to N. In contrast IRG levels in the two H+C patients were within the normal range. The impaired IRG production in A and in H (but not in H+C) suggests a close relationship between alpha pancreatic function and cortisol levels.     

Gastrointestinal/pancreatic hormone concentrations in the portal venous system of nine patients with organic hyperinsulinism

Percutaneous transhepatic sampling of blood in the portal venous system (TPVS) was used to; (1) localize hormone secreting tumors and help in differentiating tumors from diffuse disease (nesideoblastosis and hyperplasia with adenomata) in 9 patients with fasting hypoglycemia and hyperinsulinism, and (2) study the concentration an distribution of the immunoreactive peptides: insulin (IRI), gastrin (IG), glucagon (IRG), pancreatic polypeptide (hPP), and somatostatin (SRIF-LI), in the venous drainage of the uninvolved portion of the pancreas and GI tract. Localized elevations of IRI (64-920 microunits/ml) predicted tumor localization in 6 patients with single tumors that were not demonstrable angiographically. In one patient with nesideoblastosis and another with islet cell hyperplasia with adenoma, elevated IRI concentrations at multiple locations suggested a diffuse or multicentric process. Elevations of SRIF-LI in the same region as IRI elevations in one patient and of IRG in another patient suggested that these tumor produced two hormones. Some problems in the interpretation of portal venous insulin concentrations are discussed. The locations of maximum portal venous system plasma concentrations and portal-arterial gradients (mean +/- SE pg/ml) in five patients with small single insulinomas were: IG, gastrocolic trunk (126 +/- 27, 46 +/- 22); IRG, proximal splenic vein (130 +/- 30, 47 +/- 13) and gastrocolic trunk (131 +/- 23, 60 +/- 13); hPP, portal vein (164 +/- 48, 49 +/- 22); SRIF-LI, superior mesenteric vein (186 +/- 50, 57 +/- 20) and gastrocolic trunk (178 +/- 59, 55 +/- 21). It is concluded; (1) TPVS can be used successfully to localize single insulin-secreting tumors of the pancreas and to help distinguish them from diffuse disease but problems in such differentiation do occur, (2) circulating SRIF-LI and IRG are derived from both the pancreas and the gut, IG predominantly from the proximal gut and hPP from the head of the pancreas, and (3) The data provide new information for the interpretation of portal insulin concentrations in patients with organic hyperinsulinism and of hormone concentrations for localization of peptide-producing tumors of the pancreas other than insulinomas.     

Transhepatic glucagon gradients in man: evidence for glucagon extraction by human liver

Plasma samples drawn simultaneously from portal and peripheral veins during laparotomy in nine patients revealed a portal immunoreactive glucagon (IRG) level of 182 +/- 32 (+/- SEM) and a peripheral level of 117 +/- 17 pg/ml with a portal to peripheral ratio of 1.58 +/- 0.11. On gel chromatographic studies of portal-peripheral sample pairs, the portal and peripheral levels of 3500 mol wt IRG were 108 +/- 36 and 44 +/- 15 pg/ml, respectively, with a substantially greater portal to peripheral ratio (2.77 +/- 0.53). There was, however, no transhepatic gradient for the void volume IRG fraction, the other major component of plasma IRG. These results suggest that the liver in man, analogous to that in lower mammals, is an important organ for glucagon extraction.     

Metabolic effects of intranasally administered glucagon: Comparison with intramuscular and intravenous injection

Summary Intranasal administration of glucagon, 1 mg, plus sodium glycocholate 15 mg as a surfactant, raised blood glucose levels and plasma levels of immunoreactive glucagon (IRG) and immunoreactive insulin (IRI). Spray solutions were more effective than drops, and neither the surfactant alone nor glucagon alone had any effect. Blood glucose levels were similarly affected by intravenous glucagon, while intramuscular glucagon was slightly more effective. The highest IRG concentrations were reached after intravenous administration, while intramuscular injection of glucagon was accompanied by the highest IRI release. These data indicate that intranasal administration of glucagon exerts metabolic effects similar to intramuscular and intravenous administrations. Further studies are needed to improve bioavailability and efficacy of intranasally administered glucagon. Presented in part at the Symposium on Oral Administration of Peptides, organized by M. Saffran at the Annual Meeting of the American Association for the Advancement of Sciences, 26–31 May 1983, Detroit, Michigan, U.S.A.     

Pancreatic endocrine responses to nutrients and bombesin after segmental pancreas autotransplantation in dogs

The capacity of autotransplanted (ATP) distal pancreas segments with systemic venous and peritoneal exocrine drainage to support physiologic control of plasma glucose levels was tested, and compared with the functions of "simulated autotransplants" (SATP) prepared with similar dissection and peritoneal exocrine drainage, but with hepatic portal venous drainage, in dogs. In ATP in the postabsorptive state, plasma levels of glucose, immunoreactive insulin (IRI) and immunoreactive glucagon (IRG1) were normal. Autotransplants resulted in impaired glucose tolerance after meals with impaired early insulin responses, and the normal brisk rise of IRG1 in the plasma was delayed and reduced through the first 30 min of feeding. In ATP, also, the response to bombesin was abnormal; the normal stimulation of release of both IRI and IRG1 was delayed in both cases. In studies of responses to oral and intravenous glucose in ATP and SATP dogs, similar mild degrees of glucose intolerance were found with both routes of administration; however, whereas in ATP dogs increases of IRI were highly exaggerated with both routes of administration of glucose, in SATP dogs plasma IRI rose from subnormal levels in the postabsorptive state through subnormal increments with both routes of administration. Further studies are necessary to determine the relative importance of denervation and reduction of the mass of the pancreas in these effects, and to assess the significance of the differences in blood insulin levels in the two preparations.     

Gliclazide on long-term therapy increases insulin response to glucose of type II diabetics

Twelve type II diabetics were treated with gliclazide, a potent hypoglycaemic sulfonylurea, for 5 months. Plasma immunoreactive insulin (IRI), connecting peptide (C-peptide) and immunoreactive glucagon (IRG) were measured during a 2 h oral glucose tolerance test (OGTT) before and during gliclazide therapy. The OGTT improved in 7 patients. In those patients IRI concentrations were significantly more elevated during than before the treatment period. By contrast, gliclazide treatment did not affect the hepatic extraction of insulin (estimated by the molar ratio of C-peptide to IRI) nor the inappropriate glucagon release commonly observed in this type of patients.     

Nature and biologic activity of “extrapancreatic glucagon”: Studies in pancreatectomized cats

After total pancreatectomy concentrations of circulating immunoreactive glucagon (IRG) were elevated (255 ± 37 pg/ml, mean ± SEM; n = 20) in comparison to unoperated cats (119 ± 27 pg/ml). Plasma glucagon concentrations were determined in an assay regarded as specific for pancreatic glucagon. The nature of this extrapancreatic IRG was further examined in the following studies. Arginine (0.45 gm/kg i.v.) caused a marked elevation of IRG in normal animals but did not cause a consistent elevation of IRG in 6 pancreatectomized cats. Whereas somatostatin (20 μg/kg/hr i.v. for 1 hr) in 10 pancreatectomized cats caused a reduction in IRG from 195 ± 45 to 64 ± 22 pg/ml (p < 0.02), blood glucose did not change. Moreover, insulin (0.22 U/kg/hr i.v. for 1 hr) failed to reduce blood glucose levels in 6 pancreatectomized cats despite a fall in IRG from 269 ± 87 to 150 ± 62 pg/ml (p < 0.05). Glucagon (4 ng/kg/min i.v. for 1 hr) given during the second hour of somatostatin infusion failed to raise blood glucose in 7 untreated pancreatectomized cats. However, when euglycemia was achieved by prolonged insulin therapy in 2 pancreatectomized animals, extrapancreatic IRG became completely suppressed and a hyperglycemic response to exogenous glucagon was restored. Although extrapancreatic IRG appeared identical to pancreatic glucagon by immunoassay, Sephadex G50 chromatography of plasma from 4 pancreatectomized animals showed that 40%–90% of the IRG was of approximately 9000–10,000 molecular weight. Only 10%–60% was of molecular weight corresponding to pancreatic glucagon, i.e., 3500. This contrasted with normal cats, in whom more than 90% of IRG was of molecular weight 3500. The excessive secretion of extrapancreatic IRG is probably related to insulin deficiency since it is reversed by prolonged insulin therapy. The circulating material is heterogeneous and would correspond in molecular size to pancreatic glucagon and a larger molecular weight glucagon precursor. The lack of a consistent response to arginine and predominance of 9000–10,000 molecular weight material could be due to chronic hyperstimulation of true A cells situated in the upper gastrointestinal tract or other extrapancreatic sites; on the other hand, these results could suggest that the cell of origin of extrapancreatic IRG is distinct from the A cell. A major role for extrapancreatic glucagon in the hyperglycemia of diabetes is not evident in these studies, though hepatic glycogen depletion and a reduced rate of peripheral glucose utilization in the operated animals may have reduced the impact on blood glucose levels of changes in IRG. It is possible that extrapancreatic IRG contributes to the poor response to exogenous insulin and glucagon seen in untreated pancreatectomized animals.     

Hyperglucagonemia in liver cirrhosis with portal-systemic venous anastomoses: responses of plasma glucagon and gastric inhibitory polypeptide to oral or intravenous glucose in cirrhotics with normal or elevated fasting plasma glucose levels.

Plasma immunoreactive glucagon (IRG) was examined in volunteers with biopsy-proven cirrhosis of the liver after recovery from surgical portal--caval anastomosis. A wide range of increased total plasma IRG concentrations was found after overnight fast in groups of cirrhotic subjects with and without fasting hyperglycemia. Gel filtration chromatography of plasma showed a major component in the 3500-mol wt fraction in all cases so studied. Administration of glucose i.v. caused rapid suppression of total plasma IRG in normoglycemic and non-insulin-dependent hyperglycemic cirrhotic subjects. After administration of oral glucose, total plasma IRG was suppressed rapidly in normoglycemic cirrhotic subjects, while non-insulin-dependent hyperglycemic cirrhotic subjects exhibited delayed but prolonged suppression. Chromatography of selected plasma with glucose-suppressed total IRG showed a major decrease in the 3500-mol wt component in every case. Exaggerated increments of plasma gastric inhibitory polypeptide were demonstrable in both groups of cirrhotic individuals after administration of oral glucose, and it is speculated that this peptide may contribute to stimulation of glucagon secretion in liver disease associated with insulin deficiency.     

Evaluation of the control of glucagon secretion by the parasympathetic nervous system in man.

To evaluate the influence of the parasympathetic nervous system on human glucagon secretion, we have measured the plasma immunoreactive glucagon (IRG) levels after the administration of edrophonium, bethanechol chloride, and 2-deoxyglucose, and have compared the IRG responses to hypoglycemia in normal, atropinized, and vagotomized man. Edrophonium administered i.v. and bethanechol chloride administered s.c. did not affect IRG levels. Two-deoxy-glucose resulted in symptomatic neuroglucopenia with resultant vagal discharge, as evidenced by increased gastric acid secretion; but no changes in IRG concentrations were observed. The IRG response to insulin-induced hypoglycemia in normal subjects was not influenced by the administration of atropine. In seven subjects with a truncal vagotomy and no increased gastric acid secretion during insulin-induced hypoglycemia, the IRG increases were indistinguishable from those of control subjects in terms of timing, peak level obtained, or total glucagon response. We conclude that the cholinergic system is unlikely to play an important role in modulating glucagon secretion in man.     

Effects of ethanol ingestion on glucose tolerance and insulin secretion in normal and diabetic subjects

To investigate the effect of ethanol on carbohydrate homeostasis in circumstances in which food and ethanol are usually ingested, ethanol was administered hourly in the afternoon prior to the ingestion of a glucose load at 5:00 p.m. in a group of normal subjects and in mild diabetics. In both groups the blood glucose levels following the glucose load were $\text{30–80 mg}\text{100 ml}$ lower and the early insulin secretory response (15–45 min) was 35%–40% higher after ethanol ingestion. In contrast, ethanol intake had no effect on the glucagon response to glucose ingestion. These data suggest that ethanol enhances glucose-stimulated insulin secretion. The dampened blood glucose rise observed with ethanol may be related to the augmented insulin response or to decreased gastrointestinal absorption of glucose. In mild diabetic patients, moderate intake of ethanol is without acute deleterious effects on carbohydrate homeostasis and may in some instances improve the blood glucose response to ingested carbohydrate.